This Week in Science

In Science Signaling this week, researchers in the UK say amplification of oncogenes KRAS or BRAF underpins an acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. The researchers modeled acquired resistance to the MEK 1/2 inhibitor selumetinib in colorectal cancer cells with BRAF or KRAS mutations. Genomic sequencing showed no acquired mutations in MEK1 or MEK2, selumetinib's primary targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.